COVID-19: Vaccine Information, Visitor Information and What to Expect

Montlake Bridge Closure: Learn about detours to Seattle Children’s when the Montlake Bridge closes during several weekends this fall.

Learn about Seattle Children’s Health Equity and Anti-Racism Action Plan, a message from Dr. Jeff Sperring, CEO.

Current Research Studies

Cancer – AALL1521: Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Acute Lymphoblastic Leukemia

Condition or Therapy:

Category:

Cancer and blood disorders
Study Number: AALL1521

What is the goal of this study?

Researchers want to study the combination of ruxolitinib with chemotherapy in the treatement of B-cell acute lymphoblastic leukemia.

Who can join the study?

This study may be a good fit for children and young adults who:

Are between 1 and 21 years old, and
have been newly diagnosed with High-Risk, PH-like B-Accute Lymphoblastic Leukemia.

What will happen if my child takes part in this study?

You can read more about this study at clinicaltrials.gov.

Who can I contact for more information?

For more information, call 206-987-2106 or send us an email.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Colleen Annesley

Looking for a Researcher?

Name: First Name Last Name
Area of Focus: Research Center:

©1995–2021 Seattle Children’s Hospital

4800 Sand Point Way NE,

Seattle,

WA

98105

206-987-2000

866-987-2000 (toll-free)

206-987-0391 (TTY)

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.